60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

* Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026. * Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier. WASHINGTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it will disclose the outcome of the interim analysis from its clinical study evaluating tafenoquine in patients hospitalized with severe babesiosis (NCT06207370) on October 6, 2026.

In conjunction with the data release, 60 Degrees will host a Key Opinion Leader (KOL) investor webinar on Tuesday, October 6, 2026. The webinar will highlight the substantial unmet medical need for new therapeutic options in relapsing and treatment-refractory babesiosis, review the clinical data from Company’s hospital and expanded access studies and the literature, and discuss the potential role of tafenoquine in addressing recurrent tick-borne infections.